Kailos Genetics
Kailos Genetics is a CAP-accredited, CLIA-certified clinical genetics laboratory in Huntsville, Alabama, offering pharmacogenomic (Inspexion), hereditary cancer (Expedio), and preventive health (Kailos Prevent) testing built on proprietary TargetRich enrichment and NGS, serving healthcare systems, consumers, research labs, and now insurance policyholders via its healthīme parent.
- Company typePrivate
- Founded2010
- HeadquartersHuntsville, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Kailos Genetics does
Kailos Genetics is a Huntsville, Alabama-based clinical genetics company founded in 2010, operating a CAP-accredited and CLIA-certified laboratory on the HudsonAlpha Institute for Biotechnology campus. The company builds genetic testing products on its proprietary TargetRich enrichment technology combined with next-generation DNA sequencing and cloud-based analytics. Its core product portfolio comprises Inspexion (pharmacogenomic testing with 10-day turnaround), Expedio (hereditary cancer risk testing with 15-day turnaround, non-invasive buccal swab collection), and Kailos Prevent / Prevent Plus (preventive health panels aligned to CDC Tier 1 Genomic Applications). The company also sells clinical-grade reagents (Kailos Complete V6 pharmacogenomic panel, Hereditary Cancer V2.5 panel covering 26 genes) and a customizable reagent program (Kailos Flex) to research laboratories.
Kailos operates a direct-pay, no-insurance-billing model, charging flat $200-$250 per genetic screening test, which sidesteps reimbursement cycles and EOBs. Its go-to-market is hybrid: a healthcare-systems and physician partnership program distributing Expedio and Inspexion, direct-to-consumer testing (including the now-ended Information is Power community program serving North Alabama residents), B2B reagent sales to research laboratories, and — following the May 2023 acquisition by healthīme — a new embedded-insurance channel in which Kailos' testing is delivered through healthīme's health navigation platform and Hannover Re US reinsurance to life and critical insurance policyholders.
Since the May 2023 acquisition by healthīme, Kailos has functioned as a wholly-owned subsidiary with founder Brian Pollock serving as President. The company holds registered trademarks for its product brands (TargetRich, Inspexion, Expedio, Kailos Complete, Kailos Flex, ViraWash, ViralPatch, Assure Sentinel) and Medical Director Ron McGlennen, M.D., contributes nine issued and pending patents in molecular biology and genetics. Service is available throughout the U.S. with the exception of New York. Headcount is in the 11-50 range, and no institutional venture funding rounds have been disclosed beyond a 2011 round and a 2017 In-Q-Tel (IQT) investment.
Kailos Genetics firmographics
Firmographics- Name
- Kailos Genetics
- Legal name
- Kailos Genetics, LLC
- Website
- https://kailosgenetics.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kailos Genetics is a CAP-accredited, CLIA-certified clinical genetics laboratory in Huntsville, Alabama, offering pharmacogenomic (Inspexion), hereditary cancer (Expedio), and preventive health (Kailos Prevent) testing built on proprietary TargetRich enrichment and NGS, serving healthcare systems, consumers, research labs, and now insurance policyholders via its healthīme parent.
- Ownership category
- akta.pro rank
Kailos Genetics industry classification
Industry- Product category
- Clinical Genetic Testing Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
Keywords
Where Kailos Genetics is headquartered
LocationHeadquarters
- HQ city
- Huntsville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kailos Genetics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Clinical genetic testing services: Direct-pay genetic testing services including hereditary cancer risk testing and pharmacogenetic testing, billed at contracted flat rates without insurance claims.
- Laboratory reagent sales: Sale of clinical grade laboratory reagents and reagents for next-generation sequencing to research laboratories. Includes assay design services, validated protocols, and cloud-based analytic software solutions.
- COVID-19 surveillance testing: Workplace viral suppression programs using Assure Sentinel testing for organizations, schools, and healthcare partners.
- Enterprise laboratory services: Full range of laboratory services to healthŌme and other healthcare/life insurance partners, diversified beyond traditional healthcare reimbursement systems.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Genetic screening tests priced between $200-$250 |
| One time/ perpetual license | Pay-as-you-go | Pharmacogenomic testing with 10-day turnaround |
| One time/ perpetual license | Pay-as-you-go | Hereditary cancer risk testing with 15-day turnaround |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Kailos Genetics product offering
Product offeringCore offering
Kailos Genetics operates a CAP-accredited, CLIA-certified clinical laboratory providing precision medicine genetic testing services, including hereditary cancer risk testing (Expedio) and pharmacogenomic testing (Inspexion), using proprietary TargetRich enrichment technology and next-generation DNA sequencing. The company also sells clinical-grade next-generation sequencing reagents and offers customizable panel design (Kailos Flex) to research laboratories, with HIPAA-compliant cloud-based analytics and data delivery integration.
Product overview
Kailos Genetics offers a precision medicine platform built around proprietary TargetRich™ enrichment technology and next-generation DNA sequencing. The core product portfolio centers on three main testing services: Inspexion™ for pharmacogenomic testing (identifying genetic variations affecting medication metabolism), Expedio™ for hereditary cancer risk testing, and Kailos Prevent™ for high-prevalence actionable health conditions. The company also provides clinical-grade laboratory reagents through its Kailos Complete™ V6 and V2.5 panels, and offers customization through its Kailos Flex™ program. All laboratory services are delivered through a CAP-accredited, CLIA-certified facility at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama.
Differentiator
Problem solved
Functional benefit
Brands
- Inspexion: Pharmacogenomic testing service using next-generation DNA sequencing
- Expedio
- Kailos Prevent
- Assure Sentinel
- Kailos Complete
- Kailos Flex
- ViraWash
- ViralPatch
Products and services
- Inspexion Pharmacogenomic Testing Comprehensive pharmacogenetic testing service using next-generation DNA sequencing to identify genetic variations affecting medication metabolism. Provides metabolic information for key pharmacogenes with 10-day turnaround time and multiple reporting options. Designed for physicians and patients seeking to understand how genetic variations affect drug response.
- Expedio Hereditary Cancer Risk Testing Hereditary cancer mutation testing service using next-generation DNA sequencing with non-invasive buccal swab sample collection. Results delivered within 15 days with comprehensive consultations for genotypes and reported results. Designed for physicians and patients seeking hereditary cancer risk assessment.
- Kailos Prevent Genetic testing service for high-prevalence actionable conditions including cancer, heart disease, strokes, and metabolism of antidepressants and opioids. Designed around CDC Tier 1 Genomic Applications guidelines for identifying DNA changes with significant potential for positive health impact.
- Assure Sentinel COVID-19 Workplace Surveillance Testing COVID-19 workplace surveillance testing program using ViraWash non-invasive saliva-based sample collection and ViralPatch proprietary viral capture and sample pooling methodology combined with next-generation DNA sequencing. Designed for employers, non-profit organizations, and schools seeking cost-efficient testing to enable safe operations.
- Kailos Complete V6 Pharmacogenomic Panel Clinical grade next-generation sequencing reagent panel targeting pharmacogenes for pharmacogenomic testing. Sold to research laboratories as part of Kailos's complete sequencing solution that includes assay design, validated protocols, and cloud-based analytic software.
- Kailos Complete Hereditary Cancer V2.5 Panel Clinical grade next-generation sequencing reagents for hereditary cancer testing targeting 26 genes. Available as a Research Use Only (RUO) product for laboratory reagent programs, sold to research laboratories with cloud-based analytics.
- Kailos Flex Customizable Reagent Program Customizable laboratory reagent program allowing research laboratories to specify particular gene targets for their research applications. Includes cloud-based analytics software with HIPAA-compliant secure data delivery. Provides full sequencing solution from assay design to data analysis.
Quantifiable outcome
- Over 7,000 participants served through Information is Power program
- +2 more outcomes
Companies that use Kailos Genetics
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles5 records
Kailos Genetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Kailos Genetics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- University of Minnesota College of PharmacycoreEstablished pharmacogenetic testing and internship program offering Kailos Genetics' Inspexion pharmacogenetic testing service to first year pharmacy students. Through an application process, internships with Kailos Genetics are offered to University of Minnesota students focused on the utility of pharmacogenetics in healthcare. This partnership supports education and technology in genetics and pharmacy to improve patient health outcomes.
- HH Health System (Huntsville Hospital Health System)corePartnership to offer COVID-19 surveillance testing through Assure Sentinel program. HH Health System offers the service through its Corporate Wellness, Occupational Health Group, and HH Health System Reference Laboratory Network. HH Health System staff administers tests, collects samples, and communicates results to tested individuals and employers.
- Huntingdon CollegeminorCOVID-19 testing partnership for campus reopening. Huntingdon College identified access to testing as a key element to responsibly reopen campus. Kailos provided a reasonably priced, efficient testing option critical in mitigating COVID-19 spread on campus.
- HudsonAlpha Institute for BiotechnologycoreKailos Genetics is a resident company at the HudsonAlpha Institute for Biotechnology campus. Founded in 2010 and located at HudsonAlpha, Kailos is one of over 40 associate companies on the 152-acre campus. The Institute and its associated companies have had a $2.45 billion impact on the Alabama state economy. Jim Hudson, a founder of HudsonAlpha, noted the strategic fit of bringing together two HudsonAlpha associate companies.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Kailos Genetics competitors and assessment
Company assessmentDirect peers
- OneOme: OneOme specializes in pharmacogenomic testing with partner-driven distribution to hospitals and clinicians, mirroring Kailos' Inspexion PGx panel, health system partnership channel, and physician-directed positioning.
- Natera: Natera runs a CAP/CLIA-accredited molecular diagnostics lab focused on hereditary cancer screening, reproductive health, and oncology NGS — overlapping with Kailos' hereditary cancer and broader NGS-based testing portfolio.
- Ambry Genetics: Ambry (now part of Labcorp) is a CAP/CLIA-accredited specialty lab offering hereditary cancer and multi-gene NGS panels plus customizable assays — the closest large-scale analog to Kailos' clinical lab and Kailos Complete reagent model.
- Color Health: Color offers hereditary cancer, pharmacogenomics, and population health genetic testing at comparable price points ($249) with employer and health system partnerships — directly overlapping Kailos' Inspexion, Expedio, and channel motion.
- Fulgent Genetics: Fulgent offers NGS-based hereditary cancer, pharmacogenomics, and customizable clinical panels with health system partnerships — comparable to Kailos' Kailos Complete and Kailos Flex reagent/program offerings.
- GeneDx: GeneDx operates a CLIA-certified clinical lab delivering hereditary cancer, rare disease, and pharmacogenomic NGS testing with health system partnerships — directly comparable to Kailos on test menu, regulatory posture, and B2B go-to-market.
Broad incumbents
- Labcorp: Labcorp operates extensive clinical lab capacity and, through its ownership of Ambry Genetics, competes directly in hereditary cancer NGS testing, making it a broad incumbent analog to Kailos' clinical services.
- Quest Diagnostics: Quest is a large national reference lab providing genetic and molecular diagnostics including hereditary cancer screening — overlapping as a broad incumbent competitor for physician-ordered testing volume.
- 23andMe: 23andMe pioneered the direct-to-consumer genetic testing model that Kailos' Information is Power program emulated; as a broader incumbent in DTC and B2B genomics, it represents a competitive reference point on consumer channel and pricing.
- Myriad Genetics: Myriad is an established molecular diagnostics leader with a hereditary cancer franchise plus broader oncology and pharmacogenomics offerings, making it a broader incumbent peer in the same clinical genomics category.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Kailos Genetics social profiles
Digital presenceKailos Genetics compliance and trust
Trust signalCompliance3 records
Kailos Genetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kailos Genetics leadership team
Management profileNumber of profiles
Profiles8 records
Kailos Genetics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kailos Genetics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kailos Genetics
What does Kailos Genetics do?
Kailos Genetics operates a CAP-accredited, CLIA-certified clinical laboratory providing precision medicine genetic testing services, including hereditary cancer risk testing (Expedio) and pharmacogenomic testing (Inspexion), using proprietary TargetRich enrichment technology and next-generation DNA sequencing. The company also sells clinical-grade next-generation sequencing reagents and offers customizable panel design (Kailos Flex) to research laboratories, with HIPAA-compliant cloud-based analytics and data delivery integration.
Is Kailos Genetics a public or private company?
Kailos Genetics is a private company. It is classified as corporate owned and is currently operating.
When was Kailos Genetics founded?
Kailos Genetics was founded in 2010. It employs 11 to 50 people.
Where is Kailos Genetics based?
Kailos Genetics is headquartered in Huntsville, United States, in the North America region.
How does Kailos Genetics make money?
Four revenue lines are on record. Clinical genetic testing services are the primary driver. The others are laboratory reagent sales, COVID-19 surveillance testing and enterprise laboratory services.
Who are Kailos Genetics's main competitors?
Direct peers on record are OneOme, Natera, Ambry Genetics, Color Health, Fulgent Genetics and GeneDx. Broad incumbents are Labcorp, Quest Diagnostics, 23andMe and Myriad Genetics.
Does Kailos Genetics have an API?
No public API is recorded for Kailos Genetics.
What industry is Kailos Genetics in?
Kailos Genetics's product category is Clinical Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.